ClinicalTrials.gov
public full text
Public Domain
MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour
bladder-cancerbreast-cancercancerhead-and-neck-cancerlung-cancermelanomaovarian-cancerprostate-cancer
The primary objective is to determine the safety and tolerability of the novel compound, MRx0518 in patients with solid tumours at 30 days post-surgery. 20 participants will receive open label MRx0518 in a preliminary safety phase. After successful evaluation by the Independent Safety Monitoring Committee (IDMC), a further 100 participants will be recruited to receive MRx0518/Placebo.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of NOV140201 (JPI-547) in Subject With Advanced Solid Tumors#1140308
- Assess the Safety and Activity of Combined MG005 and Sorafenib (NEXAVAR®) Treatment With Solid Tumor#866963
- Clinical Trial of BT02 in Patients With Advanced Solid Tumors#832384
- A Study of MRG003 in Patients With Advanced Solid Tumors#812943
- Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors#898315
Record · ID 845831
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive